The purpose of this symposium is to update medical practitioners in the greater Midwest region as well as nationally on the future of cardiac electrophysiology (EP), and on new diagnosis and treatment guidelines in the care and management of patients with arrhythmias, heart failure and other issues impacting the electrical system of the body. Participants will learn about advances in ablation techniques, device management, appropriate use criteria, and survey new developments in guidelines and recommendations. A review of clinical trials that have helped change the clinical practice of EP will also be held. Participants in this symposium will examine the latest trends in Left Atrial Appendage (LAA) treatment options and gain a greater understanding of anticoagulation and stroke prophylaxis. The unprecedented era that healthcare providers have faced during the COVID-19 pandemic has led to countless unanswered questions and forced clinicians and patients to adapt to the current environment. Evidence indicates that COVID-19 infection and its recovery period are associated with cardiac compromise. For example, between 9%-17% of hospitalized patients with COVID-19 have evidence of arrhythmias. (Chung 2021) As such, the diagnosis, management, and risk stratification of these complications will be discussed.
The program will address the following learning objectives:
- Discuss types of devices used for monitoring and treating arrhythmias
- Demonstrate the use of imaging techniques to improve procedural outcomes
- Apply guideline-endorsed, clinically applicable strategies to help resolve device-related issues
- Summarize clinical trial results that can be applied to improving the safety and efficacy of electrophysiology (EP) procedures
- Explain anticoagulation treatment and stroke prophylaxis options for cardiac patients
- Examine clinical evidence for the latest trends in LAA treatments